Literature DB >> 8892955

Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. The UNAIDS Network for HIV Isolation and Characterization.

M Cornelissen1, G Kampinga, F Zorgdrager, J Goudsmit.   

Abstract

Genetic subtypes of human immunodeficiency virus type 1 can be distinguished on the basis of phylogenetic analysis of their envelope (env) gene. A significant proportion of human immunodeficiency virus type 1 strains was retrospectively shown to result from recombination events between viruses belonging genetically to distinct subtypes (D. L. Robertson, P. M. Sharp, F. E. McCutchan, and B. H. Hahn, Nature [London] 374:124-126, 1995). To establish the frequency of natural infections with recombinant viruses and to exclude tissue culture artifacts, we analyzed plasma samples from the UNAIDS sample collection. The collection includes samples from 53 individuals infected with subtype A (n = 9), subtype B (n = 15), subtype C (n = 1), subtype D (n = 13), and subtype E (n = 15) on the basis of V3 region analysis. Phylogenetic analysis of the gag gene fragment showed intersubtype recombinant genomes in 23 cases: 3 of 9 (33%) of subtype A, 2 of 15 (13%) of subtype B, 3 of 13 (23%) of subtype D, and all of subtype E. Of the 23 recombinant viruses, 19 had a gag gene from one subtype and env from another (B(env)/C(gag), A(env)/C(gag), D(env)/A(gag), and E(env)/A(gag)). Phylogenetic analysis clustered the A(gag) of subtype E viruses as an outgroup of subtype A, suggesting that these viruses may belong to a distinct A' cluster. The remaining four recombinant viruses (B(env)/B(p17)F(p24), A(env)/A(p17)D(p24), A(env)/A(p17)C(p24), and D(env)/ D(p17)A(p24)) had breakpoint crossover sites in the proximity of the p17-p24 protein processing site. We conclude that recombination in the gag gene is highly frequent among the major env subtypes and that selection of recombinants is apparently based on particularly beneficial combinations of gag and env gene products.

Entities:  

Mesh:

Year:  1996        PMID: 8892955      PMCID: PMC190904     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group.

Authors:  R S Diaz; E C Sabino; A Mayer; J W Mosley; M P Busch
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

2.  Early HIV type 1 strains in Thailand were not responsible for the current epidemic.

Authors:  M L Kalish; C C Luo; B G Weniger; K Limpakarnjanarat; N Young; C Y Ou; G Schochetman
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

3.  Recombination in HIV-1.

Authors:  D L Robertson; P M Sharp; F E McCutchan; B H Hahn
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

4.  Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans.

Authors:  A W Artenstein; T C VanCott; J R Mascola; J K Carr; P A Hegerich; J Gaywee; E Sanders-Buell; M L Robb; D E Dayhoff; S Thitivichianlert
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

Review 5.  A review of human immunodeficiency virus infection in India.

Authors:  M K Jain; T J John; G T Keusch
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-11

6.  Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population.

Authors:  M Cornelissen; G Mulder-Kampinga; J Veenstra; F Zorgdrager; C Kuiken; S Hartman; J Dekker; L van der Hoek; C Sol; R Coutinho
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

7.  Recombination in AIDS viruses.

Authors:  D L Robertson; B H Hahn; P M Sharp
Journal:  J Mol Evol       Date:  1995-03       Impact factor: 2.395

8.  Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin.

Authors:  J Louwagie; W Janssens; J Mascola; L Heyndrickx; P Hegerich; G van der Groen; F E McCutchan; D S Burke
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

9.  Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization.

Authors:  F De Wolf; E Hogervorst; J Goudsmit; E M Fenyö; H Rübsamen-Waigmann; H Holmes; B Galvao-Castro; E Karita; C Wasi; S D Sempala
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

10.  Similarity in env and gag genes between genomic RNAs of human immunodeficiency virus type 1 (HIV-1) from mother and infant is unrelated to time of HIV-1 RNA positivity in the child.

Authors:  G A Mulder-Kampinga; A Simonon; C L Kuiken; J Dekker; H J Scherpbier; P van de Perre; K Boer; J Goudsmit
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  33 in total

1.  Genetic analysis of a UNAIDS HIV type 1 from Brazil revealed an unexpected recombination pattern.

Authors:  Mario P S Chin; Natalia Ristic
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-21       Impact factor: 2.205

2.  Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians.

Authors:  M R Betts; J Krowka; C Santamaria; K Balsamo; F Gao; G Mulundu; C Luo; N N'Gandu; H Sheppard; B H Hahn; S Allen; J A Frelinger
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 intersubtype (B/E) recombination in a superinfected chimpanzee.

Authors:  P N Fultz; L Yue; Q Wei; M Girard
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Prevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPLICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5.

Authors:  A Holguín; B Aracil; A Alvarez; C Barros; V Soriano
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

5.  One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG.

Authors:  M P de Baar; E C Timmermans; M Bakker; E de Rooij; B van Gemen; J Goudsmit
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

Review 6.  Resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors:  D Boden; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication.

Authors:  Terence Rhodes; Heather Wargo; Wei-Shau Hu
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1.

Authors:  F Gao; D L Robertson; C D Carruthers; S G Morrison; B Jian; Y Chen; F Barré-Sinoussi; M Girard; A Srinivasan; A G Abimiku; G M Shaw; P M Sharp; B H Hahn
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Development of a nucleic acid sequence-based amplification assay that uses gag-based molecular beacons to distinguish between human immunodeficiency virus type 1 subtype C and C' infections in Ethiopia.

Authors:  Workenesh Ayele; Georgios Pollakis; Almaz Abebe; Bitew Fisseha; Belete Tegbaru; Girma Tesfaye; Yohannes Mengistu; Dawit Wolday; Bob van Gemen; Jaap Goudsmit; Wendelien Dorigo-Zetsma; Michel P de Baar
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms.

Authors:  Miguel E Quiñones-Mateu; Yong Gao; Sarah C Ball; Andre J Marozsan; Awet Abraha; Eric J Arts
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.